Avid Bioservices Inc (CDMO)

[jazzbeerman]

Duke Human Vaccine Institute: HIV/TB/Malaria vaccine project ---------


Vaccine Development
HIV | Orthopoxvirus | TB
Oral Vaccines

TB

Richard Frothingham, MD
Hua-Xin (Larry) Liao, MD, PhD
Jae-Sung Yu, PhD
Barton Haynes, MD

Over the past two years, DHVI investigators have expanded their expertise in Mycobacterium tuberculosis (MTB) and Plasmodium falciparium (malaria) research. Working with the support of a grant from the National Institutes of Health, our investigators have teamed with Dr. William Jacobs at Albert Einstein College of Medicine, Dr. Louis Miller of the NIH, and Dr. Norman Letvin of Harvard, to form an inter-institutional, interdisciplinary effort to develop an HIV, TB and malaria trivalent vaccine for children.

A major hurdle in the development of a successful TB vaccine for adults is being addressed through this DHVI program. Adults have pre-existing immune responses to environmental mycobacteria, which interfere with the immune responses and the protection generated by the current TB vaccine, BCG. These pre-existing responses may interfere with novel TB vaccine candidates. Dr. Richard Frothingham and coworkers have developed a murine model of latent M. avium infection that mimics many aspects of latent human infection with environmental mycobacteria. His lab is using this model to characterize the CD4 and CD8 components of immune responses to environmental mycobacteria that interfere with protective responses to TB vaccines, and to evaluate several proposed mechanisms for this interference. The ultimate goal is the development of TB vaccines which are effective in adults. This work is relevant to the development of vaccines against other bacteria, including Bacillus anthracis and Yersinia pestis.

http://humanvaccine.duke.edu/modules/develop/index.php?id=3


---------


j